| | |
All infections
|
Infections seen in clinic
|
All URTIs
|
URTIs seen in clinic
|
|---|
|
n = 98 (54 placebo; 44 treatment)
|
n = 63 (34 placebo; 29 treatment)
|
n = 68 (32 placebo; 36 treatment)
|
n = 55 (28 placebo; 27 treatment)
|
|---|
|
Infection hazard (HR (95% CI))
|
Placebo
|
1.00 [reference]
|
1.00 [reference]
|
1.00 [reference]
|
1.00 [reference]
|
|
Treatment
|
0.83 (0.53, 1.31)
|
0.86 (0.50, 1.50)
|
1.11 (0.75, 1.65)
|
0.98 (0.59, 1.63)
|
|
P = 0.42
|
P = 0.60
|
P = 0.62
|
P = 0.94
|
|
Infection duration (coefficient (95% CI))
|
Placebo
|
3.05 (2.35, 3.76)
|
4.15 (2.77, 5.53)
|
4.87 (3.29, 6.45)
|
5.28 (3.38, 7.18)
|
|
Treatment
|
+1.04 (-0.25, 2.32)
|
+1.64 (-0.83, 4.11)
|
+0.51 (-1.80, 2.81)
|
+0.83 (-2.05, 3.70)
|
|
P = 0.11
|
P = 0.19
|
P = 0.67
|
P = 0.57
|
|
Maximum infection symptom severity (coefficient (95% CI))
|
Placebo
|
2.19 (1.81, 2.57)
|
2.19 (1.69, 2.70)
|
2.41 (1.89, 2.93)
|
2.42 (1.85, 3.00)
|
|
Treatment
|
+0.08 (-0.49, 0.65)
|
+0.19 (-0.58, 0.95)
|
+0.03 (-0.69, 0.76)
|
-0.05 (-0.85, 0.76)
|
|
P = 0.79
|
P = 0.63
|
P = 0.93
|
P = 0.91
|
|
Total infection severity (coefficient (95% CI))
|
Placebo
|
12.26 (7.90, 16.62)
|
20.34 (9.01, 31.67)
|
25.47 (11.51, 39.43)
|
29.34 (12.28, 46.40)
|
|
Treatment
|
+2.20 (-5.09, 9.49)
|
+5.95 (-13.15, 25.05)
|
-3.89 (-21.83, 14.06)
|
-2.87 (-25.70, 19.96)
|
|
P = 0.55
|
P = 0.54
|
P = 0.67
|
P = 0.81
|
|
Average daily total infection symptom severity (coefficient (95% CI))
|
Placebo
|
4.00 (3.25, 4.75)
|
4.74 (3.52, 5.96)
|
5.28 (3.73, 6.82)
|
5.41 (3.81, 7.02)
|
|
Treatment
|
-0.26 (-1.34, 0.82)
|
-0.22 (-1.97, 1.52)
|
-1.08 (-3.00, 0.85)
|
-0.91 (-2.98, 1.16)
|
|
P = 0.64
|
P = 0.80
|
P = 0.27
|
P = 0.39
|
- Infection hazard results are presented as HR (95% CI). Results for infection duration and severity are reported as geometric mean infection severity (95% CI) and then coefficient relative to the placebo group (95% CI). Note: a greater infection severity score or greater infection duration means a more severe infection or longer duration, respectively.
